# Asthma

## Case Protocol 39 â€“ **Asthma**

**Case:**

*A 35-year-old woman was seen by her local doctor because of increasing dyspnoea over the previous 12 hours. She had suffered from asthma since childhood, requiring numerous hospital admissions, and consequently was reluctant to consult doctors or to go to hospital. Her only medication was a salbutamol puffer, used as required. She had been suffering from an upper respiratory tract infection for the past three days and had a cough productive of yellow sputum.*

[](https://lh5.googleusercontent.com/Ev6AMY9RJtJrDBOJr5xH4vQ_GSGxM3uQy6Bxcy-tIb_5BMGpjhrOf_u1yBAHdpSh6EeBHchlZwJvDgu03zRMHXJRaL8mJr2PXytbAcON8JqqFAF4KsH3t5QVn-RlP2XT7bxg0gL0RxzHIE6rPmbIVg)

*On examination, the woman was dyspnoeic at rest, having difficulty in carrying out a conversation. She was pale but not cyanosed, the chest was hyperinflated with prominent tracheal tug, and she was using accessory muscles of respiration. Bilateral inspiratory and expiratory wheezes were heard on auscultation. She was commenced on antibiotics, nebulised salbutamol and prednisone tablets, but refused admission to hospital.*

- Clinical features of asthma
    - Episodic bouts of:
        - Dyspnoea
        - Wheeze
        - Chest tightness
        - Cough
    - Often worse at night time or in the early morning
    - Some mild cases may have cough-predominant/as the only symptom
- Triggers for an asthma exacerbation
    - Infection â†’ **URTI (recurrent, esp. viral)**
    - Non-infectious
        - **Poor treatment adherence or technique**
        - Exposure to irritants
            - **Smoking** (active or passive), air pollution
        - Exposure to allergens
            - Dust mites, black mould
            - Storms (aerosolise rye grass particles)
            - Pets
            - Associated with allergic rhinitis or sinusitis
        - Cold air, exercise
        - Medications
            - B-blockers (inhibition of bronchodilation)
            - NSAIDs (trigger some asthmatics)
- Management of an acute asthma attack
    - Urgent management
        - Primary survey (A-E) and concurrent resuscitation and stabilisation
            - Ensure airway patency
            - Establish IV access, fluid resuscitation (20mL/kg IV fluid bolus ASAP)
            - Establish vital monitoring
            - Supplemental O2 if < 95% (HFNP)
        - Perform initial severity assessment (informs frequency and route of drug administrations)
    - Initial pharmacological management
        - Bronchodilators
            - Salbutamol (SABA)
                - Dose: 100mcg per puff
            - Ipratropium bromide (SAMA)
                - Dose: 21mcg per puff
        - Corticosteroid therapy (**as soon as practical, at least within 1st hour**)
            - PO prednisone (preferred)
            - IV hydrocortisone (if severe, status)
    - Perform secondary assessment and continue therapy
        - Consider transfer to ICU/HDU
        - Consider additional drugs
            - Additional bronchodilators (last-line)
                - IV MgSO4
                - IV aminophyllline
            - Consider possibility of anaphylaxis if life-threatening and unresponsive to bronchodilators
                - IM 1:1000 adrenaline (0.5mL)
            - Consider antibiotics if infective exacerbation
                - Amoxicillin +/- doxycycline
- How do you assess severity of acute asthma?
    
    
    | Life threatening | Severe | Mild-moderate |
    | --- | --- | --- |
    | Altered LoC | Increased WOB (accessory muscles, tracheal tug, subcostal recession, abdominal breathing)  | Can walk and can speak whole sentences in one breath |
    | Exhaustion | Unable to complete sentences in one breath due to dyspnoea | SpO2 > 94% |
    | Cyanosis | SpO2 90-04% |  |
    | SpO2 < 90% |  |  |
    | Poor respiratory effort  |  |  |
    | Soft or absent breath sounds |  |  |
- How would you adjust management based on severity of acute asthma
    - Note
        - pMDI: pressured metered dose inhaler
        - Dosing of SABA and SAMA
            - 1-5 years old
                - Mild-moderate: **2-6 puffs SABA**
                - Severe
                    - Salbutamol: 6x puffs
                    - Ipratropium: 4x puffs
            - â‰¥ 6 years old
                - Mild-moderate: **4-12 puffs SABA**
                - Severe
                    - Salbutamol: 12x puffs
                    - Ipratropium: 8x puffs
    
    Immediate intervention (rapid severity assessment on presentation)
    
    |  | Life-threatening | Severe | Mild-moderate |
    | --- | --- | --- | --- |
    | Salbutamol | Give via continuous nebulisation (driven by O2) | Give via pMDI with spacer if tolerated, or intermittent nebulisation | Give via pMDI with spacer |
    | Ipratropium | Give via intermittent nebulisation | Consider starting via pMDI with spacer if tolerated, or intermittent nebulisation | Not indicated immediately |
    | Oxygen | Usually required, use to drive nebuliser | May be required (start if < 95%) | Not generally required |
    
    Stabilisation (after secondary severity assessment) - within minutes
    
    |  | Life-threatening | Severe | Mild-moderate |
    | --- | --- | --- | --- |
    | Continue salbutamol | Continuous nebulisation until dyspnoea improves. Then change to intermittent or pMDI with spacer | Repeat dose ever 20 mins (sooner if required) | Repeat dose if, or when, wheeze returns |
    | Start or continue ipratropium | Continue via intermittent nebulisation every 20 mins (max of 3 doses in first hour) | Consider continuing, or starting, via pMDI with spacer or intermittent nebulisation every 20 mins (max of 3 doses in the first hour) | If not responding to salbutamol, consider via pMDI with spacer every 20 mins (max of 3 doses in the first hour) |
    | Corticosteroids | Give first dose, PO preferred | Give first dose, PO preferred | Give first dose, PO preferred |
    
    Formal reassessment of response (at 1 hour)
    
    |  | Life-threatening | Severe | Mild-moderate |
    | --- | --- | --- | --- |
    | Continue salbutamol | Continuous nebulisation until dyspnoea improves. Then change to intermittent or pMDI with spacer | Repeat dose ever 20 mins (sooner if required) | Repeat doses as required, attempt to lengthen dose interval in a stepwise fashion |
    | Continue ipratropium | Repeat dose every 4-6h | Repeat dose every 4-6h PRN | Repeat dose every 4-6h PRN |
    | Add on treatments | Consider: IV MgSO4, IV aminophylline | Consider: IV MgSO4 | Not required |
    | Location of ongoing care | Anticipate HDU or ICU transfer or retrieval | Arrange hospital admission in appropriate environment based on response | May or may not required admission depending on response to therapy and other factors |
- Indications for discharge after acute asthma
    - Adequate oxygenation and oral intake without medical help
    - Ability to administer own puffer with good technique
    - PRN salbutamol stretched to > 3-hourly
    - Written asthma plan and/or adequate patient education
    - Confirmed outpatient appointment within 3 days
- Assessing baseline asthma control
    - A means of describing the patientâ€™s baseline function between attacks
    - Questions (in the last 4 weeks)
        - How many days have you had symptoms
        - How many nights have you had symptoms?
            - Has it woken you up at night?
            - How bad are your early-morning symptoms
        - How often have you needed your reliever?
        - Have you had limitations due to your symptoms?
    - Interpretation
        - Good
            - Daytime symptoms < 2 days
            - Night time symptoms - none
            - Reliever use < 2 times/week
            - Limitations - none
        - Partial (1-2 opposite answer for good)
        - Poor (3+ opposite answer for good)
- Investigative approach to acute asthma
    - Acute phase - goal to establish severity and exclude DDx
        - Bedside
            - Primary survey, vitals monitoring
                - Pulse oximetry
                - ECG - rule out cardiac causes
            - Consider sputum MCS
            - Blood gas (signs of respiratory failure)
        - Labs
            - FBC (WCC in infection)
            - CRP
            - UEC and LFT
            - Consider serum tryptase (rule out anaphylaxis)
        - Imaging
            - CXR - rule out DDx (pneumonia, pneumothorax)
- Definitive diagnosis of asthma
    - Diagnosis requires both:
        - Clinical features (episodic, with triggers)
            - Cough
            - Wheeze
            - Dyspnoea
        - Demonstration of variable expiratory airflow obstruction
            - Spirometry
                - Obstructive pattern (FER < LLN - normal FER 0.8-1.2)
                    - Improves secondary to bronchodilator admission (second test 20 mins after bronchodilators)
                    - **FEV1 must improve by 12% or 200mL**
                - Bronchoprovocation testing
                    - Attempt to induce bronchoconstriction with methacholine (dose lowered than that which would cause bronchoconstriction in a typical patient)
                        - Assess for airway hypersensitivity and reactivity
                        - If FEV1 decreases by 15% â†’ asthma
                    - Safety measures (resuscitation) must be available
- Interpret this ABG (asthma)
    
    ![Screenshot 2023-07-23 at 10.33.35 am.png](Asthma%201300acf2446a81cabbe3f1c513a261f8/Screenshot_2023-07-23_at_10.33.35_am.png)
    
    - Low pH - acidosis
        - Low O2 - hypoxaemia
        - High PaCO2 - hypercapnia (inadequate alveolar ventilation)
        - Normal HCO3 (no metabolic compensation)
    - Consistent with acute type 2 respiratory failure and uncompensated respiratory acidosis
- Definition and pathophysiology of asthma
    - Asthma is a chronic inflammatory disorder of the airways, with a variable clinical story that may include dyspnoea, wheeze, chest tightness and cough
        - Associated with variable, partially reversible airway limitation and bronchial hyperresponsiveness
    - Pathophysiology
        - Heterogenous and incompletely understood
            - Many cases are related to atopy (type 1 hypersensivity) however others are not (e.g. occupational exposures, pharmacological - aspirin)
                - Most common atopic pattern is **eosinophilic with Th2 cell recruitment** (also neutrophilic, mixed inflammatory, pauci-granulocytic)
        - Common pathophysiological pathways
            - Functional abnormalities
                - Variable, reversible increase in airway resistance (bronchoconstriction, mucus plugging, airway oedema)
                - Airway hyperresponsiveness
            - Airway inflammation
                - Vascular congestion
                - Cellular infiltrate (eosinophils or neutrophils)
            - **Airway remodelling - long term pathological changes**
                - Bronchial smooth muscle hypertrophy and hyperplasia
                - Goblet cell hyperplasia
                - Subepithelial collagen accumulation
                - Increased vascularity
- Autopsy findings in asthma
    - Macroscopic
        - Hyperinflation of lungs (secondary to air-trapping from obstruction)
        - Mucous plugs in bronchi/bronchioles
        - Areas of collapse/atelectasis
        - Areas of pneumonic consolidation
    - Microscopic
        - **Acute asthma: bronchial and bronchiolar inflammation**
            - Vascular congestion
            - Cellular infiltrate
        - **Chronic asthma: airway remodelling**
            - Bronchial smooth muscle hypertrophy and hyperplasia
            - Goblet cell hyperplasia
            - Subepithelial collagen accumulation
            - Increased vascularity
        - Other features
            - Curschmann spirals (whorls of shed epithelium in mucous plugs)
            - Charcot-Leyden crystals (eosinophilic needle-like crystals due to breakdown of eosinophils)
- Treatment paradigm for long-term prevention
    - A stepwise approach is taken to treat asthma long-term
        - Aim for good symptom control with the lowest possible dose of medication
    - Escalate treatment after 1-3 months if good control is not achieved
        - Consider other factors if poor response:
            - Inhaler technique
            - Adherence
            - If symptoms are related to asthma or alternate diagnosis
    - Steps
        - Step 1: PRN reliever (SABA)
        - Step 2: Low dose ICS + PRN SABA
        - Step 3: ICS + LABA combination (low dose) + PRN SABA
        - Step 4: ICS + LABA (medium to high dose) + PRN SABA
        - Step 5: consider specialist referral for additional treatments (e.g. immunotherapy)
    
    ![Screenshot 2023-07-23 at 10.43.30 am.png](Asthma%201300acf2446a81cabbe3f1c513a261f8/Screenshot_2023-07-23_at_10.43.30_am.png)
    

## Memorandum â€“ **Asthma (Pharm)**

**Case:** *A 36-year-old woman presents to ED with tachycardia, tachypnoea, hypotension, peripheral cyanosis and a silent chest with past history of asthma. Administration of salbutamol was not effective.*

*Her vitals were as follows ðŸ¡ª HR 150, BP 90/50, RR 36 and normal urinalysis*

*ABG:*

- *pH 7.3 (low)*
- *Oxygen: 75 mmHg (low)*
- *Carbon dioxide: 50 mmHg (high)*
- *Bicarbonate: 26 (high normal)*
- *Base excess -6 (-3 to 3)*
- *Oxygen saturation 76%*

- PDx and DDx for acute dyspnoea
    - PDx: shock secondary to status asthmaticus (acute exacerbation of asthma which is unresponsive to initial bronchodilators)
        - Patient Hx of asthma, signs and symptoms of acute airway obstruction
        - Medical emergency which needs to be managed in an high acuity setting (resuscitation bed, ICU)
    - DDx for acute or subacute dyspnoea
        - Respiratory
            - Airway: foreign body aspiration, anaphylaxis, AECOPD
            - Parenchyma: APO, pneumonia
            - Other: pneumothorax, PE
        - Cardiac
            - Ischaemic (MI), arrhythmia, cardiac tamponade
        - Other: anxiety (psychogenic)
- Explain how to use an inhaler +/- spacer
    - Pressured metered-dose inhaler
        - Hold inhaler upright and shake well
        - Breathe out gently away from inhaler
        - Create good seal around the mouthpiece
            - Breathe in slowly and at the same time, press firmly on the canister
            - Keep breathing in slowly and deeply and hold breath for about 5s or as long as comfortable
            - While holding breath, remove inhaler
        - Breathe out gently away from the inhaler
        - Repeat
    - pMDI + spacer
        - Hold inhaler upright and shake well before inserting into spacer
        - Create good seal around mouthpiece
            - Breathe out gently into spacer
        - Hold spacer level and press down firmly on inhaler canister once
            - Tidal breathing (breathe in and out normally for 3-4 breaths before removing spacer from mouth)
        - Breathe out gently
        - Repeat
- How would you stabilise the BP of a patient in shock due to an asthma attack
    - Positional
        - Elevate legs
    - Fluid resuscitation
        - Normal saline (0.9% NaCl) bolus (20mL/kg) over 10 mins
    - Pharmacological
        - Adrenaline +/- metaraminol (inotrope + vasopressor)
- Indications for ventilation
    - Clinical factors: severity of illness, response to Tx, likelihood of decline
    - Factors which may influence decision making
        - Inadequate oxygenation
            - SpO2 < 90%
            - PaO2 < 50 mmHg
        - Inadequate ventilation
            - RR > 25 breaths/min
            - PaCO2 > 50mmHg
        - Inability to protect airway (GCS < 8)
- What medications can be taken for exercise induced asthma
    - Many patients with EIA find symptomatic relief with SABA administration prior to exercise
    - Other specific agents may work:
        - Leukotriene receptor antagonists (e.g montelukast)
        - Mast cell stabilisers (e.g. sodium cromoglycate)
- How would you monitor her asthma treatment
    - Formally monitor and review the patientâ€™s progress (frequency depends on severity)
    - Disease control
        - History
            - Frequence of reliever medication use
            - Symptoms (inc. interval symptoms - night time waking, exercise)
            - Triggers or risk factors for adverse outcomes (smoking, allergens, irritants)
        - Physical examination
        - Spirometry or lung function tests (normal year-year variation up to 15%)
    - Treatment issues
        - Inhaler technique
        - Adherence
        - Check written asthma action plan and patient understanding
    - Monitor and manage comorbidities
    - Consider whether a step-up or down of medication is indicated
- What is an asthma action plan
    
    ![Screenshot 2023-11-08 at 9.58.37â€¯pm.png](Asthma%201300acf2446a81cabbe3f1c513a261f8/Screenshot_2023-11-08_at_9.58.37_pm.png)
    
    ![Screenshot 2023-11-08 at 9.59.01â€¯pm.png](Asthma%201300acf2446a81cabbe3f1c513a261f8/Screenshot_2023-11-08_at_9.59.01_pm.png)
    

- Muscarinic antagonists
    - e.g. ipratropium bromide (SAMA), tiotropium bromide (LAMA)
    - Mechanism
        - Antagonist at ACh receptors â†’ inhibits bronchoconstriction
    - AEs
        - Tachycardia
        - Nausea and vomiting
        - Dry mouth, constipation
        - Blurred vision
- Mast cell stabiliser in asthma (EIA)
    - e.g. sodium cromoglycate
    - Mechanism
        - Inhibits release of inflammatory mediators from mast cells
    - AEs
        - Cough and throat irritation
        - Bitter taste
        - Transient bronchospasm
- Leukotriene antagonists
    - e.g. montelukast (PO)
    - Mechanism
        - Competitive antagonist of the cysteinyl leukotriene receptor (CysLT1) and blocks the action of LTD4 and secondary ligands LTC4 and LTE4
        - Antagonises bronchoconstriction
    - AEs
        - Headache
        - Abdominal pain, nausea and vomiting
        - Diarrhoea
        - Rashes
        - Fever
        - Behavioural change
- Corticosteroid medications
    - Examples
        - ICS for asthma: fluticasone, budesonide
        - PO: prednisone, prednisolone, dexamethasone
    - Mechanism
        - Crosses the cell membrane and binds to intracellular glucocorticoid receptor
            - Interacts with DNA sequences to modulate transcription
        - Effects
            - Inhibits **NF-kB** to modulate gene transcription **(decreased cytokine production)**
            - Decreased activity of PMNs and macrophages (inhibits genes for adhesion factors + relevant cytokines)
            - Decreased action of Th cells and reduced clonal expansion
    - AEs
        - Impaired healing, dermal thinning, easy bruising
        - Muscle atrophy
        - Osteoporosis
        - Hyperglycaemia, diabetes
        - Cushingâ€™s syndrome
        - Fat redistribution (buffalo hump, moon facies)
        - Infections (e.g. oral candidiasis)
        - Peptic ulcer disease
        - Amenorrhoea
        - Avascular necrosis of femur
- Combination therapies in asthma
    - Seretide = fluticasone (ICS) + salmeterol (LABA)
    - Symbicort = eformoterol (LABA) + budesonide (ICS)
    - Trelegy = fluticasone (ICS) + vilanterol (LABA) + umeclidinium (LAMA)
- B2 agonists in asthma
    - Short-acting
        - Reliever medication for rapid symptom relief
        - E.g. salbutamol (100mcg)
    - Long acting
        - Used in combination with ICS for long-term maintenance control of asthma
        - E.g. salmeterol
    - Mechanism
        - Agonist at B2 adrenergic receptors â†’ relaxes bronchial smooth muscle
        - Weak effect at stabilising mast cells
    - AEs
        - Agitation, anxiety, tremor
        - Tachycardia (B1 effect)
        - Insomnia
        - Tolerance due to overuse
- Aminophylline
    - Xanthine â†’ analogous to theophylline
    - Mechanism
        - Inhibits phosphodiesterase â†’ increase cAMP
        - Bronchodilation and possibly inhibits inflammatory cell activation
    - AEs
        - Arrhythmias
        - Convulsions
        - Nausea and vomiting
        - Sudden death

- Problems with prolonged LABA use
    - Tolerance
    - Reduced sensitivity to salbutamol effects
    - LABA monotherapy associated with increased mortality
- What biologics are used in asthma
    - Anti-IgE therapy (omalizumab)
    - Anti-IL5 (mepolizumab)
    - Anti-IL4 receptor a-subunit
        - Dupilumab